
ITRM Stock Forecast & Price Target
ITRM Analyst Ratings
Bulls say
Iterum Therapeutics PLC is positioned favorably in the pharmaceutical market due to its development of Orlynvah, an innovative oral and intravenous branded penem that effectively targets complicated urinary tract infections (UTIs) caused by drug-resistant bacteria. The company's sulopenem has shown remarkable clinical efficacy in patients with quinolone-resistant infections, demonstrating improvements in overall response rates at key clinical assessment points, which enhances its appeal among healthcare providers. Additionally, the favorable safety profile of sulopenem differentiates it from other antimicrobials, suggesting strong potential for adoption by physicians, which supports a positive outlook for the company's stock.
Bears say
Iterum Therapeutics PLC faces a challenging financial outlook primarily due to depressed forward multiples influenced by current market volatility, indicating a lack of investor confidence in the company's prospects. Additionally, the company’s cash burn may be substantial as pre-commercial activities ramp up, despite the potential for revenue support from partners or collaborative milestone payments. Furthermore, the increasing prevalence of antibiotic-resistant strains of bacteria could limit the overall market demand and therapeutic applicability for Orlynvah, complicating the company's growth potential in an already competitive landscape.
This aggregate rating is based on analysts' research of Iterum Therapeutics Plc and is not a guaranteed prediction by Public.com or investment advice.
ITRM Analyst Forecast & Price Prediction
Start investing in ITRM
Order type
Buy in
Order amount
Est. shares
0 shares